[{"id":"paper-druker-imatinib-phase1-nejm-2001","kind":"paper","name":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia","route":"/key-papers/paper-druker-imatinib-phase1-nejm-2001/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/key-papers/blood-immune-cell.ts","type":"changed","fields":[{"field":"whatItMeans","before":"\"This is the paper that turned the idea of hitting a cancer's specific molecular engine into a working medicine. For people with CML it began the shift from a fatal disease treated with interferon or transplant to one...","after":"\"Druker's 2001 imatinib paper turned the idea of hitting a cancer's specific molecular engine into a working medicine. For people with CML it began the shift from a fatal disease treated with interferon or transplant ..."}]},{"id":"paper-druker-imatinib-phase1-nejm-2001","kind":"paper","name":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia","route":"/key-papers/paper-druker-imatinib-phase1-nejm-2001/","commit":"65911992ce","date":"2026-09-08","author":"Jude Gomila","message":"Key papers: haematological malignancies and immune/cell therapy","file":"src/data/key-papers/blood-immune-cell.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"tldr"},{"field":"summary"},{"field":"journal"},{"field":"year"},{"field":"doi"},{"field":"authors"},{"field":"paperType"},{"field":"findings"},{"field":"whatItMeans"},{"field":"caveats"},{"field":"changedPractice"},{"field":"participants"},{"field":"links"},{"field":"cancers"},{"field":"drugs"},{"field":"targets"},{"field":"companies"},{"field":"related"},{"field":"bottlenecks"}]}]